Compare Stocks: COYA, PROK, AVTE, and EIKN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$13.76 +2.4%	$18.28	$89.95 ▼ $99.05	$398.83M	0.95	53,591 shs	1.04 million shs
COYA Coya Therapeutics	$4.25 -2.1%	$4.76	$3.71 ▼ $7.55	$101.81M	0.58	156,997 shs	134,191 shs
EIKN Eikon Therapeutics	$7.42 -1.6%	$9.41	$6.45 ▼ $17.40	$408.40M	N/A	620,045 shs	482,772 shs
PROK ProKidney	$1.33 -8.6%	$1.68	$1.30 ▼ $3.48	$439.88M	1.77	1.72 million shs	1.66 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+2.38%	-2.76%	-20.83%	-34.04%	+50.38%
COYA Coya Therapeutics	-2.07%	-14.14%	-4.71%	-6.39%	-36.66%
EIKN Eikon Therapeutics	-1.59%	-0.67%	-12.81%	-24.05%	+741,999,900.00%
PROK ProKidney	-8.59%	-23.56%	-28.11%	-17.90%	-58.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$13.76 +2.4%	$18.28	$89.95 ▼ $99.05	$398.83M	0.95	53,591 shs	1.04 million shs
COYA Coya Therapeutics	$4.25 -2.1%	$4.76	$3.71 ▼ $7.55	$101.81M	0.58	156,997 shs	134,191 shs
EIKN Eikon Therapeutics	$7.42 -1.6%	$9.41	$6.45 ▼ $17.40	$408.40M	N/A	620,045 shs	482,772 shs
PROK ProKidney	$1.33 -8.6%	$1.68	$1.30 ▼ $3.48	$439.88M	1.77	1.72 million shs	1.66 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+2.38%	-2.76%	-20.83%	-34.04%	+50.38%
COYA Coya Therapeutics	-2.07%	-14.14%	-4.71%	-6.39%	-36.66%
EIKN Eikon Therapeutics	-1.59%	-0.67%	-12.81%	-24.05%	+741,999,900.00%
PROK ProKidney	-8.59%	-23.56%	-28.11%	-17.90%	-58.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	260.78% Upside
EIKN Eikon Therapeutics	2.56	Moderate Buy	$24.67	232.43% Upside
PROK ProKidney	2.67	Moderate Buy	$12.00	802.26% Upside

Current Analyst Ratings Breakdown

Latest COYA, PROK, AVTE, and EIKN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	EIKN Eikon Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$23.00
10/15/2026	COYA Coya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/6/2026	PROK ProKidney	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/25/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/16/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/15/2026	COYA Coya Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$16.00
9/7/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
8/24/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/24/2026	COYA Coya Therapeutics	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$12.00
8/21/2026	EIKN Eikon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
8/14/2026	EIKN Eikon Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Underperform	$5.00 ➝ $4.00

(Data available from 10/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
COYA Coya Therapeutics	$7.95M	12.54	N/A	N/A	$2.06 per share	2.06
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	$890K	451.78	N/A	N/A	($3.36) per share	-0.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
COYA Coya Therapeutics	-$21.23M	-$1.07	N/A	N/A	N/A	-270.22%	-52.05%	-46.34%	11/11/2026 (Estimated)
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	-$68.99M	-$0.55	N/A	N/A	N/A	-10,288.39%	N/A	-27.39%	11/9/2026 (Estimated)

Latest COYA, PROK, AVTE, and EIKN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	COYA Coya Therapeutics	-$0.35	N/A	N/A	N/A	$0.11 million	N/A
11/9/2026	Q3 2026	PROK ProKidney	-$0.12	N/A	N/A	N/A	$0.13 million	N/A
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.3457	-$0.28	+$0.0657	-$0.28	$0.13 million	$0.24 million
8/10/2026	Q2 2026	PROK ProKidney	-$0.14	-$0.15	-$0.01	-$0.15	$0.19 million	$0.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
COYA Coya Therapeutics	N/A	13.40	13.40
EIKN Eikon Therapeutics	N/A	9.89	9.89
PROK ProKidney	N/A	8.36	8.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
COYA Coya Therapeutics	39.75%
EIKN Eikon Therapeutics	N/A
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
COYA Coya Therapeutics	6.10%
EIKN Eikon Therapeutics	N/A
PROK ProKidney	39.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
COYA Coya Therapeutics	8	23.46 million	22.03 million	Not Optionable
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A
PROK ProKidney	231	302.32 million	181.91 million	Optionable

COYA, PROK, AVTE, and EIKN Headlines

Recent News About These Companies

Why ProKidney Corp.’s (PROK) Stock Is Down 5.15%

October 16 at 6:01 PM | aaii.comA

ProKidney Corp. (PROK) Stock Earnings Call Transcripts - Yahoo Finance

October 15 at 12:51 AM | finance.yahoo.com

ProKidney (NASDAQ:PROK) Shares Down 6% - Here's Why

October 14 at 2:21 AM | americanbankingnews.com

ProKidney (NASDAQ:PROK) Stock Price Down 6% - Here's Why

October 14 at 2:19 AM | marketbeat.com

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

October 2, 2026 | markets.businessinsider.com

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026

October 2, 2026 | globenewswire.com

ProKidney consensus price target increased by 22.40% to MX$116.87

September 29, 2026 | msn.com

ProKidney (NASDAQ:PROK) Stock Price Down 7.6% - Should You Sell?

September 21, 2026 | marketbeat.com

ProKidney (PROK) Stock Forecast & Price Target

September 19, 2026 | investing.com

ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict

September 11, 2026 | finance.yahoo.com

ProKidney Corp. (PROK) Options Chain - Yahoo Finance

August 26, 2026 | finance.yahoo.com

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)

August 14, 2026 | seekingalpha.com

ProKidney (PROK) Receives a Hold from Morgan Stanley

August 14, 2026 | theglobeandmail.com

ProKidney (PROK) Receives a Hold from Morgan Stanley

August 14, 2026 | theglobeandmail.com

ProKidney (PROK) Gets a Buy from Guggenheim

August 12, 2026 | theglobeandmail.com

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

August 10, 2026 | zacks.com

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

August 10, 2026 | manilatimes.netM

ProKidney Cell Therapy Thwarts Onerous Dialysis

July 30, 2026 | bloomberg.com

ProKidney Corp. (PROK) Latest Stock News & Headlines - Yahoo Finance

July 14, 2026 | finance.yahoo.com

ProKidney Corp (NASDAQ: PROK) - Share Price and Research

July 13, 2026 | intelligentinvestor.com.auI

What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite?

July 9, 2026 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, PROK, AVTE, and EIKN Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$13.76 +0.32 (+2.38%)

As of 10/15/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Coya Therapeutics NASDAQ:COYA

$4.25 -0.09 (-2.07%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$4.26 +0.01 (+0.35%)

As of 10/16/2026 07:30 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Eikon Therapeutics NASDAQ:EIKN

$7.42 -0.12 (-1.59%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$7.40 -0.01 (-0.20%)

As of 10/16/2026 07:30 PM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

ProKidney NASDAQ:PROK

$1.33 -0.13 (-8.59%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$1.32 -0.02 (-1.13%)

As of 10/16/2026 07:58 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, PROK, AVTE, and EIKN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, PROK, AVTE, and EIKN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, PROK, AVTE, and EIKN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, PROK, AVTE, and EIKN Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Coya Therapeutics NASDAQ:COYA

Eikon Therapeutics NASDAQ:EIKN

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, PROK, AVTE, and EIKN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, PROK, AVTE, and EIKN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, PROK, AVTE, and EIKN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, PROK, AVTE, and EIKN Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Coya Therapeutics NASDAQ:COYA

Eikon Therapeutics NASDAQ:EIKN

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools